Pulling SEC filings + quote and writing the call…
BRKR
BRUKER CORP
Next earnings Aug 3, 2026 (before open) · consensus $0.39 EPS, $870M rev
Last earnings +11.3% on 2026-05-06
$57.27
▲ +0.06%$57.23▲ +47.04%
over 1Y
L $29.23EODHDH $62.70
Earnings Dividend Split Congress buy Congress sellFilings colored by tone · hover for detail
Today+0.1%
1W+3.7%
1M+34.4%
3M+70.4%
YTD+19.1%
1Y+47.0%
Hold
Conviction
Horizon
Medium (3–12mo)
Street · 22 analysts
Buy
High-quality scientific-instruments franchise hit by a sharp 2025 margin collapse and a GAAP loss; cheaper, but the trajectory is negative.
Bruker is a developer of high-performance scientific instruments and analytical/diagnostic systems across four segments (BioSpin, CALID, NANO, BEST). FY2025 was a clear step backward. Revenue rose only 2.1% to $3.44B, but the quality of that growth was poor: management's own non-GAAP organic revenue fell 3.7% and constant-currency revenue was -0.2%, meaning the headline growth came from acquisitions and currency, not the underlying business. Profitability deteriorated sharply — GAAP operating income collapsed 73.1% to $68.2M (a 2.0% margin versus 7.5% in 2024), gross margin fell to 45.9% from 49.0%, and the company swung to a net loss of -$8.60M (EPS -$0.15). Operating cash flow nearly halved to $134M.
Sources: SEC EDGAR (CIK 0001109354, latest 10-Q filed 2026-05-07) · EODHD · analysis by claude-code · as of 6/21/2026, 8:49:39 PM.
Research and education only — not financial advice. Calls are generated from SEC filings and a delayed/third-party price feed, may be wrong or out of date, and are not a recommendation to buy or sell any security. Do your own research.